Revvity (RVTY) is trading lower today as the stock digests a negative shift in Street sentiment, led by a Barclays downgrade to Equalweight from Overweight with a reduced price target. Additional price-target revisions posted around the same period have added to the pressure, pushing the name lower even without a new earnings release today. (marketscreener.com)

The downgrade lands as investors remain focused on Revvity’s 2026 setup, where management has guided to 2%–3% organic revenue growth and adjusted EPS of $5.35–$5.45. With the stock recently trading around the low-$90s, incremental caution from large brokers can quickly translate into multiple compression for slower-growth life-science tools and diagnostics names. (ir.revvity.com)

Near-term attention turns to whether additional firms follow with downward estimate revisions or further target resets, and whether Revvity can show improving demand trends that support its 2026 guidance. Separately, the company has also announced a regular quarterly dividend payable May 8, 2026, with an April 17, 2026 record date, but that action is not typically enough to offset a sentiment-driven selloff tied to rating changes. (s202.q4cdn.com)